Inovio Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
INO Inovio Pharmaceuticals Inc
VIVC Vivic Corp
BAC Bank of America Corp
DGRW WisdomTree U.S. Quality Dividend Growth Fund
DFP Flaherty & Crumrine Dynamic Preferred and Income Fund
DFP Flaherty & Crumrine Dynamic Preferred and Income Fund
DES WisdomTree U.S. SmallCap Dividend Fund
DEO Diageo PLC
DDF Delaware Investments Dividend and Income Fund
DAL Delta Air Lines Inc
Go

Health Care : Biotechnology | Mid Cap Blend
Company profile

Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Premarket

Last Trade
Delayed
$21.47
0.54 (2.58%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$20.93
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
7,334

10-day average volume:
88,421,776
7,334

INOVIO 24 HOUR DEADLINE ALERT: FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Deadline in Class Action Lawsuit Against Inovio Pharmaceuticals - INO

10:50 pm ET May 11, 2020 (PR Newswire) Print

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until May 12, 2020 to file lead plaintiff applications in a securities class action lawsuit against Inovio Pharmaceuticals (NasdaqGS: INO), if they purchased the Company's shares between February 14, 2020 and March 9, 2020, both dates inclusive (the "Class Period"). This action is pending in the United States District Court for the Eastern District of Pennsylvania.

https://mma.prnewswire.com/media/399590/Kahn_Swick_and_Foti_Logo.jpg

What You May Do

If you purchased shares of Inovio and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-ino/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by May 12, 2020.

About the Lawsuit

Inovio and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On March 9, 2020, pre-market, Citron Research published a statement highlighting the Company's "ludicrous and dangerous claim that they designed a [COVID-19] vaccine in 3 hours" and calling for an SEC investigation into the claims.

On this news, the price of Inovio's shares plummeted damaging investors, closing at $5.70 per share on March 10, 2020, a drop of 71%.

The case is McDermid v. Inovio Pharmaceuticals, Inc., et al., 2:20-cv-01402.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. KSF serves a variety of clients - including public institutional investors, hedge funds, money managers and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLCLewis Kahn, Managing Partnerlewis.kahn@ksfcounsel.com1-877-515-18501100 Poydras St., Suite 3200New Orleans, LA 70163

https://c212.net/c/img/favicon.png?sn=DA04754&sd=2020-05-11

View original content to download multimedia:http://www.prnewswire.com/news-releases/inovio-24-hour-deadline-alert-former-louisiana-attorney-general-and-kahn-swick--foti-llc-remind-investors-with-losses-in-excess-of-100-000-of-deadline-in-class-action-lawsuit-against-inovio-pharmaceuticals---ino-301057161.html

SOURCE Kahn Swick & Foti, LLC

https://rt.prnewswire.com/rt.gif?NewsItemId=DA04754&Transmission_Id=202005112250PR_NEWS_USPR_____DA04754&DateId=20200511

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.